Artwork

Inhalt bereitgestellt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!

LuTectomy in European Urology

44:50
 
Teilen
 

Manage episode 381609574 series 3350113
Inhalt bereitgestellt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.
Even better on our YouTube channel
Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.
Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.
Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:

LuTectomy paper in European Urology
LuTectomy Editorial

  continue reading

157 Episoden

Artwork

LuTectomy in European Urology

GU Cast | Urology Podcast

12 subscribers

published

iconTeilen
 
Manage episode 381609574 series 3350113
Inhalt bereitgestellt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.
Even better on our YouTube channel
Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.
Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.
Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:

LuTectomy paper in European Urology
LuTectomy Editorial

  continue reading

157 Episoden

모든 에피소드

×
 
Loading …

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.

 

Kurzanleitung